The newest antigen products from ACROBiosystems, which target the newly discovered Omicron mutation BA.2.75, have recently been announced.
Since May, BA.2.75 has been rapidly dispersing throughout India. Numerous other nations, including the United Kingdom, the United States, Australia, Germany, etc., have reported new connected cases since the identification of this novel mutation.
BA.2.75, unofficially called “Centaurus,” has been classified as a Variant of Interest (VOIs) instead of a Variant of Concern (VOCs) by the World Health Organization (WHO). Although the harm posed by this newly discovered Omicron mutation is not yet known, its existence is keeping health professionals worldwide on their toes.
Dr. Maria Van Kerkhove, the WHO’s COVID-19 technical head, reported that there are insufficient numbers of samples for the proper examination of BA.2.75. Only 200 sequences have so far been gathered from 14 different nations, which is a significant barrier to comprehending this mutation.
A high level of immune evasion has become the standard for newer variants because the vast majority of the population has been vaccinated against COVID-19. As a result, despite a sizable population that has received vaccinations, increased infection rates by novel COVID variants can be anticipated.
Similar findings from a recent study by Yamasoba, et al. support this. Out of the ten therapeutic monoclonal antibodies that were tested against BA.2.75 and other novel variants, the majority of the approved therapies failed when it came to neutralizing the COVID variants, especially BA.2.75.2
Beyond sharing the same high-level variant structure as Omicron BA.2, Centaurus (BA.2.75) differs from the other Omicron subvariants in that it has a few additional changes. According to a comparison of the two variants’ sequences, BA.2.75 has 17 more nucleotide mutations than BA.2.
The Spike protein has several important mutations, including G446S and Q493R, which have notable antigen-converting effects. According to earlier research, the Q493R mutation may boost the virus’ affinity for the ACE2 receptor, whereas the G446S mutation is one of the most efficient immune escape locations.
Image Credit: ACROBiosystems
The long-term COVID vaccination strategy has been called into doubt by the existence of these novel, more contagious COVID variants.
The idea of using a “booster shot” rather than creating a new vaccination to tackle the new variants is becoming more and more accepted among specialists. Two prospective boosters for the Omicron subvariants are anticipated to be available this fall, according to a recent statement from Moderna.
Figure 2. Neutralization assays were performed using pseudoviruses harboring the SARS-CoV-2 Spike proteins of BA.2, BA.4/5, and BA.2.75. Image Credit: Yamasoba, et al2
The extremely contagious BA.5 Omicron subvariant of COVID-19 continues to be the predominant coronavirus strain in many nations. BA.5 made up 52% of the sequence library, based on information from the Global Initiative on Sharing All Influenza Data (GISAID).
The study also reveals that the nominal value for infectiousness, known as the R0 value, is 18.6. This makes it the most contagious subvariant of the SARS-CoV-2 virus and is around six times as contagious as the wild type.
The newest BA.2.75 antigen-related products from ACROBiosystems have been made available to aid in the creation of vaccines that are designed to combat more recent COVID variants and to satisfy the market’s increasing needs. With the development of COVID-19, ACROBiosystems hopes to continually provide the Spike timer, S RBD, and Nucleocapsid protein, which are crucial antigens for vaccine research.
- Provides Spike trimer, S RBD, S1, S2, NTD, and N protein in biotinylated and unconjugated versions
- Covers nearly all new Omicron subvariants: BA.4/5, BA.2.74/75/76, BA.2.38, etc.
- Purity is over 95% verified by SDS-PAGE and over 90% determined by MALS
- High bioactivity confirmed by strict quality control, which is appropriate for ELISA/SPR/BLI and other experiments
The purity of SARS-CoV-2 Spike Trimer, His Tag (BA.2.75/Omicron) (Cat. No. SPN-C522f) is more than 90% verified by SEC-MALS. The molecular weight of this protein is around 496–548 kDa. Image Credit: ACROBiosystems
Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 Spike Trimer, His Tag (BA.2.75/Omicron) (Cat. No. SPN-C522f) at 1 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2–16 ng/mL (QC tested). Image Credit: ACROBiosystems
SARS-CoV-2 Spike Trimer, His Tag (BA.2.75/Omicron) (Cat. No. SPN-C522f) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (Cat. No. SPD-M265) with a linear range of 0.1–2 ng/mL (Routinely tested). Image Credit: ACROBiosystems
- Topol, E., 2022. BA.5, Chapter 2. [online] Erictopol.substack.com. Available at: https://erictopol.substack.com/p/ba5-chapter-2.
- Yamasoba D, Sato K, et al, 2022. Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies. The Lancet Infectious Diseases.
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control, and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
To respond to the coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD, and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantities.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.